Brain-Penetrant HDAC6 Imaging Agents for Selective Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing HDAC inhibitors are non-selective, leading to undesired side effects, and designing brain-penetrant HDAC6 selective agents has been challenging, with limited understanding of HDAC6 expression in the living human brain and high doses often required for functional effects.
Innovation Solution
Development of a brain-penetrant, selective HDAC6 inhibitor compound, suitable for PET imaging, which can selectively inhibit HDAC6 and be used for treating diseases associated with abnormal HDAC activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective HDAC inhibitors are used, then HDAC activity is inhibited, but undesired side effects occur due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing HDAC6-selective inhibitors with specific molecular structures (Formula I compounds) that target only HDAC6 and not other HDAC isoforms. The selective binding pharmacophore includes specific substituents (R1-R5, X1-X3, L1-L2) that confer HDAC6 selectivity, thereby inhibiting HDAC6 activity while avoiding the side effects caused by non-selective inhibition of other HDAC isoforms.
2Reliability
If high doses of HDAC6 inhibitors are used, then functional effects are achieved, but toxicity and side effects increase
Solution Approach 1:
The patent applies parameter changes by optimizing the pharmacological parameters of HDAC6 inhibitors through structural modifications. The compounds of Formula I are designed with specific substituents (R1-R5 groups, X1-X3 linkages, L1-L2 connectors) that enhance binding affinity and selectivity for HDAC6, enabling functional effects at lower doses and reducing toxicity associated with high-dose administration.
3Reliability
If brain-penetrant HDAC6 selective inhibitors are designed, then selective inhibition is achieved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the HDAC6 inhibitor design into distinct pharmacological modules: a core scaffold (Formula I structure), specific substituent groups (R1-R5), linkage elements (L1-L2), and stereochemical configurations (X1-X3). This modular approach allows systematic optimization of selectivity and brain penetration while managing development complexity through structured compound synthesis and characterization.
Data Source
AI summary
Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.